PKR1 Antibody

What is PKR1 and why is it important in research?

Prokineticin Receptor 1 (PKR1), also known as ZAQ or GPR73a, is a 7-transmembrane glycoprotein belonging to the G-protein coupled receptor (GPCR) family. PKR1 plays crucial roles in mediating the effects of prokineticins 1 and 2, including regulation of angiogenesis in endocrine glands and stimulation of gastrointestinal smooth muscle contraction . The extracellular portions of human PKR1 share 81% amino acid identity with mouse PKR1 and 78% with human PKR2, with most non-identical regions located in the N-terminal sequences. PKR1's involvement in these physiological processes makes it a significant target for investigating various biological systems and potential therapeutic interventions.

How do I select the appropriate PKR1 antibody for my research?

Selection should be based on your specific experimental requirements:

When selecting, verify species reactivity (human, mouse, rat), epitope location, and prior validation in your application of interest. Many commercially available antibodies are raised against N-terminal regions of human PKR1 , which may affect cross-species applications.

What controls are essential when working with PKR1 antibodies?

Implementing proper controls is crucial for reliable experimental results:

• Positive Control: Use cell lines or tissues known to express PKR1 (e.g., human monocytes)

• Negative Control: Include samples from PKR1-knockout models or use isotype control antibodies (e.g., Catalog # MAB0041 for flow cytometry)

• Loading Control: For Western blot, include housekeeping proteins (β-actin, GAPDH)

• Peptide Competition Assay: Pre-incubate antibody with immunizing peptide to confirm specificity

• Cross-Reactivity Assessment: Test against closely related proteins (e.g., PKR2) to ensure specificity

How should I optimize Western blot protocols for PKR1 detection?

Successful Western blot detection of PKR1 requires careful optimization:

• Sample Preparation: Use protein extraction buffers containing protease inhibitors to prevent degradation of membrane proteins

• Protein Loading: Load 20-50 μg of total protein per lane

• Antibody Dilution: Start with manufacturer's recommended range (1/500-1/3000) and optimize

• Blocking Solution: Use 5% non-fat dry milk or BSA in TBST

• Incubation Time: Primary antibody incubation at 4°C overnight generally yields better results

• Detection Method: HRP-conjugated secondary antibodies with enhanced chemiluminescence provide good sensitivity

• Membrane Selection: PVDF membranes may provide better retention of membrane proteins than nitrocellulose

Consider that PKR1, being a GPCR, may form aggregates during sample preparation. Sample heating and strong detergents may be necessary, but optimize to maintain epitope integrity.

What are the optimal conditions for flow cytometric detection of PKR1?

Based on validated protocols for PKR1 detection in human monocytes :

• Cell Preparation: Isolate cells and maintain viability >90%

• Cell Concentration: Adjust to 1×10^6 cells/100 μL in staining buffer

• Blocking: Fc block (10-15 minutes) to reduce non-specific binding

• Primary Antibody Incubation: Human Prokineticin R1/PKR1 Monoclonal Antibody (e.g., Clone #420849) at optimized concentration

• Secondary Detection: If using unconjugated primary antibody, use fluorophore-conjugated secondary antibody (e.g., Allophycocyanin-conjugated Anti-Mouse IgG)

• Controls: Include isotype control (e.g., MAB0041) and unstained cells

• Analysis: Gate on viable cells and assess PKR1 expression compared to isotype control

When analyzing tissue samples, enzymatic dissociation methods should be optimized to preserve the PKR1 epitope on the cell surface.

How can I accurately quantify PKR1 protein levels using ELISA?

For quantitative measurement of PKR1 in human tissue homogenates and biological fluids:

• Sample Preparation:

  • Tissue homogenates: Homogenize in PBS (pH 7.2-7.4) and centrifuge

  • Cell culture supernatants: Centrifuge to remove particulates

  • Serum samples: Use undiluted or make appropriate dilutions

• ELISA Protocol:

  • Use pre-coated microplates with PKR1-specific antibody

  • Add standards or samples to wells

  • Add biotin-conjugated antibody specific to PKR1

  • Add Avidin-HRP conjugate

  • Add TMB substrate and measure at 450nm

• Data Analysis:

  • Generate standard curve using serial dilutions

  • Determine PKR1 concentration by comparing sample OD to standard curve

  • Account for any dilution factors in final calculation

Ensure all reagents are equilibrated to room temperature before use, and perform all incubations at recommended temperatures for optimal enzymatic activity.

How can I distinguish between PKR1 and the closely related PKR2 in my experiments?

Distinguishing PKR1 from PKR2 is critical due to their 78% amino acid identity in extracellular portions :

• Antibody Selection: Choose antibodies raised against N-terminal sequences where non-identity mainly occurs

• Validation Methods:

  • Western blot with recombinant PKR1 and PKR2 proteins

  • Immunoprecipitation followed by mass spectrometry

  • PKR1-specific siRNA knockdown to confirm antibody specificity

• Expression Analysis:

  • RT-qPCR to distinguish mRNA expression of both receptors

  • Co-staining with validated PKR1 and PKR2 antibodies in tissue sections

• Functional Assays:

  • Use receptor-specific antagonists in signaling assays

  • Evaluate different downstream signaling pathways (may be receptor-specific)

If available, PKR1-knockout models provide definitive controls for antibody specificity assessment.

What approaches can I use to study PKR1 receptor occupancy and internalization?

Understanding receptor dynamics requires specialized techniques:

• Receptor Occupancy Assays:

  • Flow cytometry-based methods using competing labeled ligands

  • Radioligand binding assays with PKR1-specific ligands

  • BRET/FRET approaches with tagged receptors and ligands

• Internalization Studies:

  • Live-cell imaging with fluorescently tagged antibodies

  • Surface biotinylation followed by internalization period

  • Flow cytometry comparing surface vs. total receptor pools

  • Confocal microscopy with membrane markers

• Quantification Methods:

  • Calculate percent receptor occupancy from binding curves

  • Measure internalization rate as function of surface receptors over time

  • Analyze colocalization with endosomal markers

These approaches provide insights into receptor pharmacology and trafficking dynamics that are essential for understanding PKR1 function in different cell types.

How can I investigate PKR1 signaling pathways in different cell types?

PKR1 signaling studies require multiple complementary approaches:

• Pathway Analysis Tools:

  • Phospho-specific antibodies for downstream effectors

  • Calcium mobilization assays (PKR1 activates Gq-coupled pathways)

  • cAMP accumulation assays

  • ERK/MAPK activation studies

• Cell Type Considerations:

  • Expression levels may vary considerably between tissues

  • Signaling machinery differences may affect coupling efficiency

  • Consider endogenous ligand production in the experimental system

• Experimental Designs:

  • Time-course studies (seconds to hours)

  • Dose-response relationships

  • Inhibitor studies to determine pathway dependencies

  • Comparison with PKR2-mediated signaling

Document cell type-specific signaling profiles to understand the functional consequences of PKR1 activation in different physiological contexts.

How do I address common issues with PKR1 antibody performance in Western blot applications?

For membrane proteins like PKR1, denaturation conditions are critical. Try different sample buffer compositions and heating times to optimize protein solubilization while maintaining epitope recognition.

What storage and handling practices maximize PKR1 antibody performance and longevity?

Proper antibody handling is crucial for consistent results:

• Storage Recommendations:

  • Store at -20°C to -70°C for long-term preservation

  • Avoid repeated freeze-thaw cycles by preparing small aliquots

  • Short-term storage (1 month) at 2-8°C under sterile conditions after reconstitution

  • Medium-term storage (6 months) at -20°C to -70°C under sterile conditions

• Handling Practices:

  • Thaw aliquots completely before use and mix gently

  • Briefly centrifuge before opening vials to collect all material

  • Use sterile techniques when handling stock solutions

  • Return to recommended storage conditions immediately after use

• Quality Control:

  • Document lot numbers and performance characteristics

  • Test new lots against previous lots for consistency

  • Include positive controls in each experiment to verify antibody performance

Some antibodies contain preservatives like sodium azide (0.02%) - be aware of potential incompatibilities with your experimental system.

How do I interpret contradictory results when using different PKR1 detection methods?

When faced with conflicting data from different detection methods:

• Method-Specific Considerations:

  • Western blot detects denatured protein which may not reflect native conformation

  • Flow cytometry and immunohistochemistry detect native protein but may have accessibility issues

  • ELISA sensitivity depends on antibody pair selection and sample preparation

• Systematic Validation:

  • Use multiple antibodies targeting different epitopes

  • Compare results with mRNA expression data (RT-qPCR)

  • Verify with functional assays (receptor signaling)

  • Include positive and negative control samples in all methods

• Reconciliation Approaches:

  • Consider post-translational modifications that affect antibody recognition

  • Evaluate subcellular localization (membrane vs. internalized receptor)

  • Assess potential sample processing effects on epitope availability

  • Document method-specific detection limits

Contradictory results often reflect biological complexity rather than technical failure. Thoroughly document all experimental variables to identify patterns that explain discrepancies.

How can PKR1 antibodies be used in investigating disease mechanisms?

PKR1 is implicated in several pathophysiological processes that can be investigated using specific antibodies:

• Cardiovascular Research:

  • Angiogenesis regulation in heart tissues

  • Cardiomyocyte survival pathways

  • Endothelial cell migration and proliferation

• Gastrointestinal Disorders:

  • Smooth muscle contraction alterations

  • Inflammatory bowel disease mechanisms

  • Enteric nervous system regulation

• Endocrine System Dysfunction:

  • Hormone secretion modulation

  • Endocrine gland vascularization

  • Metabolic syndrome correlations

The research approach should combine antibody-based detection methods with functional assays to establish causative relationships between PKR1 expression/activity and disease progression.

What novel techniques are enhancing PKR1 antibody applications in research?

Emerging methodologies are expanding the utility of PKR1 antibodies:

• High-Content Imaging:

  • Automated quantification of receptor localization

  • Multi-parameter analysis of signaling events

  • 3D tissue analysis of receptor distribution

• Single-Cell Techniques:

  • Mass cytometry (CyTOF) for multi-parameter analysis

  • Single-cell Western blot for heterogeneity studies

  • Imaging mass cytometry for tissue architecture analysis

• Proximity Labeling Methods:

  • BioID or APEX2 approaches to identify interaction partners

  • Spatially-resolved interactome analysis

  • Temporal mapping of signaling complexes

These advanced techniques provide unprecedented spatial and temporal resolution for studying PKR1 biology in complex systems.